We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
+0.36%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$250M
AUM Growth
+$113M
Cap. Flow
+$139M
Cap. Flow %
55.71%
Top 10 Hldgs %
70.9%
Holding
100
New
34
Increased
19
Reduced
25
Closed
17

Top Buys

1
TENX icon
Tenax Therapeutics
TENX
+$13M
2
CAMP icon
CAMP4 Therapeutics
CAMP
+$5.51M
3
VSTM icon
Verastem
VSTM
+$3.52M
4
CRIS icon
Curis
CRIS
+$3.41M
5
SLGL icon
Sol-Gel Technologies
SLGL
+$2.01M

Top Sells

1
INDV icon
Indivior Pharmaceuticals
INDV
+$3.59M
2
IKT icon
Inhibikase Therapeutics
IKT
+$2.47M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$2.39M
4
ELDN icon
Eledon Pharmaceuticals
ELDN
+$2.02M
5
EDSA icon
Edesa Biotech
EDSA
+$1.97M

Sector Composition

1 Healthcare 45.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCSA icon
76
Processa Pharmaceuticals
PCSA
$6.39M
$139K 0.06%
55,000
+42,677
+346% +$117K
CABA icon
77
Cabaletta Bio
CABA
$461M
$135K 0.05%
50,000
-121,100
-71% -$336K
KLRS
78
Kalaris Therapeutics
KLRS
$104M
$118K 0.05%
+20,400
New +$181K
ELDN icon
79
Eledon Pharmaceuticals
ELDN
$314M
$108K 0.04%
35,000
-858,100
-96% -$2.02M
OVID icon
80
Ovid Therapeutics
OVID
$455M
$88.8K 0.04%
40,000
-62,367
-61% -$112K
EVAX
81
Evaxion A/S
EVAX
$25.7M
$73.3K 0.03%
19,713
-287
-1% -$1.09K
MNKD icon
82
MannKind Corp
MNKD
$1.25B
$39.9K 0.02%
16,300
-70,059
-81% -$313K
BCAB icon
83
BioAtla
BCAB
$6.56M
$10.5K ﹤0.01%
+1,308
New +$15.3K
ACAD icon
84
Acadia Pharmaceuticals
ACAD
$4.38B
– –
-100,000
Closed -$2.39M
CRSP icon
85
CALL
CRISPR Therapeutics
CRSP
$4.71B
– –
-50,000
Closed -$2.62M
DAWN
86
DELISTED
Day One Biopharmaceuticals
DAWN
– –
-200,000
Closed -$1.86M
DCTH icon
87
Delcath Systems
DCTH
$442M
– –
-27,232
Closed -$264K
ENTA icon
88
Enanta Pharmaceuticals
ENTA
$400M
– –
-100,000
Closed -$1.58M
FENC icon
89
Fennec Pharmaceuticals
FENC
$365M
– –
-50,000
Closed -$385K
GERN icon
90
Geron
GERN
$924M
– –
-805,800
Closed -$1.06M
GOSS icon
91
Gossamer Bio
GOSS
$83.2M
– –
-204,770
Closed -$635K
INDV icon
92
Indivior Pharmaceuticals
INDV
$4.79B
– –
-100,000
Closed -$3.59M
KPRX icon
93
Kiora Pharmaceuticals
KPRX
$11.7M
– –
-131,144
Closed -$258K
KZR
94
DELISTED
Kezar Life Sciences
KZR
– –
-156,179
Closed -$982K
MIST icon
95
Milestone Pharmaceuticals
MIST
$148M
– –
-662,666
Closed -$1.34M
NKTR icon
96
CALL
Nektar Therapeutics
NKTR
$2.31B
– –
-50,000
Closed -$2.11M
RARE icon
97
CALL
Ultragenyx Pharmaceutical
RARE
$2.88B
– –
-100,000
Closed -$2.3M
SMLR
98
DELISTED
Semler Scientific
SMLR
– –
-50,000
Closed -$765K
TNYA icon
99
Tenaya Therapeutics
TNYA
$177M
– –
-352,001
Closed -$250K
SPRB
100
Spruce Biosciences
SPRB
$120M
– –
-19,742
Closed -$1.72M
1 2 3
4

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
TGP
TMT General Partner Hong Kong $250M AUM 6.05% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return

Stonepine Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Stonepine Capital Management held 100 positions worth $250M, up 82% from $137M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Stonepine Capital Management deployed $139M of net new capital in Q1 2026, opening 34 new positions and adding to 19 existing holdings. Its largest new stake was Sol-Gel Technologies: 27,778 shares worth $2.2M.

By sector, the portfolio is most concentrated in Healthcare at 46% of assets, down from 92% a quarter earlier.

On the sell side, the largest reduction was Inhibikase Therapeutics, an estimated $2.47M trimmed.

  • Stonepine Capital Management's largest Q1 2026 buy was Sol-Gel Technologies: 27,778 shares worth $2.2M.
  • Stonepine Capital Management added most to Tenax Therapeutics in Q1 2026, an estimated $13M increase.
  • Stonepine Capital Management's biggest Q1 2026 reduction was Inhibikase Therapeutics, cutting an estimated $2.47M.
  • Stonepine Capital Management fully exited Indivior Pharmaceuticals in Q1 2026, selling an estimated $3.59M.
  • Stonepine Capital Management's ten largest holdings make up 71% of its $250M portfolio in Q1 2026.
  • Stonepine Capital Management opened 34 new positions and closed 17 in Q1 2026.
  • Stonepine Capital Management's portfolio value rose 82% quarter-over-quarter to $250M.

Based on Stonepine Capital Management's 13F filing for Q1 2026, filed 14 May 2026.